Medium platelet volume as a noninvasive predictor of chronic total occlusion in non-infarct artery in patients with non-ST-segment elevation myocardial infarction and multivessel coronary artery disease

详细信息    查看全文

• 作者：Mateusz Tajstra ; ^{mateusztajstra@wp.pl} ; Michał Hawranek ; Piotr Desperak ; Aneta Ciślak ; Marek Gierlotka ; Andrzej Lekston ; Lech Poloński ; Mariusz Gąsior
• 关键词：Mean platelet volume ; Chronic total occlusion ; Non-ST-segment elevation myocardial infarction ; Percutaneous coronary intervention
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：228
• 期：Complete
• 页码：594-598
• 全文大小：309 K
• 卷排序：228

文摘

Chronic total occlusion (CTO) in a noninfarct-related artery (non-IRA) is an independent predictor of mortality in non-ST elevation myocardial infarction (NSTEMI). Mean platelet volume (MPV) is associated with cardiovascular events in NSTEMI. Little is known about the predictors of non-IRA-CTO in patients with NSTEMI. The purpose of this study was to evaluate the relationship between the presence of non-IRA-CTO with MPV level in patients with NSTEMI and multivessel coronary artery disease (MVCAD).MethodsData of consecutive patients with NSTEMI and MVCAD treated in high-volume PCI center between 2006 and 2012 and included in the prospective registry were divided according to the presence of CTO and analyzed.ResultsIn the group of 685 patients fulfilling the inclusion criteria, 308 (45%) patients had CTO (CTO +), and in 377 (55%) patients CTO was not observed (CTO −). The MPV level on admission was significantly higher in the CTO + group than in the CTO − group (P < 0.0001). In the multivariate analysis of the entire study population, independent predictors of occurrence of CTO were medium platelet volume (MPV; per 1 fL more; odds ratio [OR] 1.34; 95% confidence interval [CI] 1.15–1.57; P = 0.0002) together with left ventricular ejection fraction and prior MI.ConclusionsMPV at admission is independently associated with more frequent occurrence of non-IRA CTO in patients with NSTEMI and MVCAD.